Pfizer this week announced the launch of a new research and development network, which aims to build upon its new areas of expertise, following the company's recent merger with Wyeth.
Incorporating the strengths of both organisations, the network will aim to bolster research methods, focusing specifically on the areas of disease and making the best use of the property owned by the firms.
Part of the plans include downsizing for the sake of concentrating operations, as research and development activities will now be conducted at five main sites and nine specialised units around the world.
Mikael Dolsten, president of biotherapeutics research and development at the company, commented: "This new structure puts Pfizer in the best position to conduct cutting-edge research within and beyond our own laboratories and to deliver a portfolio of high-impact medicines to patients."
Last week, Pfizer reported that its treatment CHANTIX/CHAMPIX (varenicline) was found to help 42.3 per cent of smokers with chronic obstructive pulmonary disease cease their habits.
NEWS BY INDUSTRY
